Cancer-associated thrombosis (including venous thromboembolism (VTE) and arterial
events) is highly consequential for patients with cancer and is associated with worsened …

Recent studies have demonstrated a role of neutrophils in both venous and arterial
thrombosis. A key prothrombotic feature of neutrophils is their ability to release web-like …

Objective To assess rates of cardiovascular and haemostatic events in the first 28 days after
vaccination with the Oxford-AstraZeneca vaccine ChAdOx1-S in Denmark and Norway and …

Thrombosis is a major complication of cardiovascular disease, leading to myocardial
infarction, acute ischemic stroke, or venous thromboembolism. Thrombosis occurs when a …

The association between inflammation, infection, and venous thrombosis has long been
recognized; yet, only in the last decades have we begun to understand the mechanisms …

Antiplatelet agents and anticoagulants are a mainstay for the prevention and treatment of
thrombosis. However, despite advances in antithrombotic therapy, a fundamental challenge …

Multiple mechanisms mediate thrombin generation and consequently the thrombin
concentration present during fibrin formation. First, the levels of pro-and anticoagulants …

Thrombolysis with tissue plasminogen activator (tPA) provides the most common therapy for
ischemic stroke onset within the past 4.5 h. However, enhanced neutrophil infiltration and …

The immunoglobulin receptor GPVI (glycoprotein VI) is selectively expressed on
megakaryocytes and platelets and is currently recognized as a receptor for not only collagen …

Thrombotic cardio‐cerebrovascular diseases seriously threaten human health. Currently,
conventional thrombolytic treatments are challenged by the low utilization, inferior thrombus …